. 2019 Feb 15;10(2):114–132. doi: 10.4239/wjd.v10.i2.114

Table 3.

Observational studies

S. No	Ref.	Design	Inclusion criteria	Age (yr)	Male gender	Sample size	SGLT-2 inhibitor	Follow-up duration
1	Ohki et al[15], 2016	Prospective study	Type 2 diabetes with NAFLD treated with GLP-1 analogues or DPP-4 inhibitors and failed to normalise serum ALT levels	54.2 (49.3-60.1)	19 (79.2%)	24	Ipragliflozin 25-50 mg daily	320 d (302-329)
2	Seko et al[16], 2016	Retrospective cohort study	Type 2 diabetes with NAFLD	SGLT-2 inhibitor arm: 60.3 (1.8)	SGLT-2 inhibitor arm: 9 (37.5%)	24 (SGLT-2 inhibitor); 21 (Sitagliptin )	Canagliflozin 100 mg (n = 18) or Ipragliflozin 50 mg daily (n = 6)	24 wk
2	Seko et al[16], 2016	Retrospective cohort study	Type 2 diabetes with NAFLD	Sitagliptin arm: 59.4 (3.7)	Sitagliptin arm: 8 (38.1%)	24 (SGLT-2 inhibitor); 21 (Sitagliptin )		24 wk
3	Gautam et al[17], 2018	Prospective study	Type 2 diabetes with NAFLD	-	-	32	Canagliflozin 100 mg daily	24 wk
4	Sumida et al[18], 2018	Prospective study	Age > 20 yr, HbA1c > 6.5% to < 8.5%, NAFLD	55.4 (13.6)	28 (70%)	40	Luseogliflozin 2.5 mg daily	24 wk

NAFLD: Non-alcoholic fatty liver disease; SGLT-2: Sodium glucose cotransporter-2; GLP-1: Glucagon like peptide-1; DPP-4: Dipeptidyl peptidase-4.